BioXcel Therapeutics is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.57 – an increase of 0.4% over the previous week. BioXcel Therapeutics employs 74 staff and has a trailing 12-month revenue of around $2.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.57 |
|---|---|
| 52-week range | $0.50 - $4.17 |
| 50-day moving average | $0.60 |
| 200-day moving average | $1.62 |
| Wall St. target price | $4.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.46 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.588 from 2024-11-20
| 1 week (2024-11-14) | 12.99% |
|---|---|
| 1 month (2024-10-21) | 7.06% |
| 3 months (2024-08-21) | -13.59% |
| 6 months (2024-05-21) | -70.75% |
| 1 year (2023-11-21) | -84.92% |
|---|---|
| 2 years (2022-11-21) | -95.94% |
| 3 years (2021-11-19) | 25.42 |
| 5 years (2019-11-21) | 6.02 |
| Revenue TTM | $2.4 million |
|---|---|
| Gross profit TTM | $355,000 |
| Return on assets TTM | -63.62% |
| Return on equity TTM | -1766.94% |
| Profit margin | 0% |
| Book value | $-1.89 |
| Market Capitalization | $23.2 million |
TTM: trailing 12 months
We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $0.5 up to $4.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 0.289. This would suggest that BioXcel Therapeutics's shares are less volatile than average (for this exchange).
BioXcel Therapeutics, Inc. , a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.